Exelixis (EXEL) Cash from Operations (2010 - 2026)
Exelixis (EXEL) posted quarterly Cash from Operations of 251845000.0 for Q2 2026, up 19.11% year-over-year from 211437000.0 in Q2 2025, and down 24.49% quarter-over-quarter from 333515000.0 in Q1 2026.
Exelixis (EXEL) Cash from Operations (2010 - 2026) Analysis & Trends
Exelixis' Cash from Operations history runs 17 years deep, the most recent figure standing at 251845000.0 for Q2 2026.
- In Q2 2026, Cash from Operations rose 19.11% year-over-year to 251845000.0; the TTM figure through Apr 2026 stood at 924675000.0 (up 9.74% YoY), while the FY2026 annual figure was 884267000.0, up 26.33% from the prior year.
- Cash from Operations for Q2 2026 stood at 251845000.0, down from 333515000.0 in the prior quarter.
- The five-year high for Cash from Operations was 333515000.0 in Q1 2026, with the low at 10571000.0 in Q4 2023.
- The 5-year median for Cash from Operations is 119548000.0 (2024), against an average of 148942411.76.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations tumbled 85.66% in 2023, then jumped 2172.85% in 2025.
- Exelixis' Cash from Operations stood at 73694000.0 in 2022, then sank by 85.66% to 10571000.0 in 2023, then surged by 2466.81% to 271338000.0 in 2024, then climbed by 7.0% to 290322000.0 in 2025, then declined by 13.25% to 251845000.0 in 2026.
- Business Quant data shows EXEL's Cash from Operations at 251845000.0 in Q2 2026, 333515000.0 in Q1 2026, and 290322000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 307.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 307.74 Mn |
| Jul 3, 2026 | 307.74 Mn |
| Apr 3, 2026 | 251.85 Mn |
| Apr 3, 2026 | 251.85 Mn |
| Jan 2, 2026 | 333.52 Mn |
| Jan 2, 2026 | 333.52 Mn |
| Oct 3, 2025 | 290.32 Mn |
| Oct 3, 2025 | 290.32 Mn |
| Jul 4, 2025 | 48.99 Mn |
| Jul 4, 2025 | 48.99 Mn |
| Apr 4, 2025 | 211.44 Mn |
| Apr 4, 2025 | 211.44 Mn |
| Jan 3, 2025 | 240.26 Mn |
| Jan 3, 2025 | 240.26 Mn |
| Sep 27, 2024 | 271.34 Mn |
| Sep 27, 2024 | 271.34 Mn |
| Jun 28, 2024 | 119.55 Mn |
| Jun 28, 2024 | 119.55 Mn |
| Mar 29, 2024 | 68.82 Mn |
| Mar 29, 2024 | 68.82 Mn |